An in-depth look at this medical topic, providing essential context for patients and caregivers.
General Medical Overview
Adrenocortical carcinoma: A condition categorized under Endocrine, Head, Neck & Skin.
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy arising from the adrenal cortex. Approximately 60% are functional, producing excess cortisol (Cushing syndrome), aldosterone, or androgens. ACC can occur sporadically or as part of Li-Fraumeni syndrome (TP53) or Beckwith-Wiedemann syndrome. Mitotane (an adrenolytic drug) is the cornerstone of systemic therapy.
Typical Treatment Roadmap
Detection
Symptoms and initial checkup.
Diagnosis
Biopsy and clinical imaging.
Treatment
Therapy (Surgery, Chemo, etc.)
Monitoring
Follow-up and recovery.
Clinical Manifestation (Main Symptoms)
Clinically, the initial presentation of Adrenocortical carcinoma often manifests with Fatigue and Weight Loss.
Advanced Stage Signs (Warning)
Cushing syndrome (weight gain, moon face, striae, hypertension), virilization in women (androgens), Conn syndrome (hypokalemia, hypertension), large abdominal mass, and IVC tumor thrombus.
Diagnostic Procedures
CT showing large (>4cm) adrenal mass with irregular enhancement and washout characteristics, 24-hour urine cortisol, androgens/estrogens, aldosterone/renin ratio, dexamethasone suppression test, and biopsy only for suspected metastases (not primary — risk of seeding).
Medical Risk Factors
Li-Fraumeni syndrome (TP53), Beckwith-Wiedemann syndrome, Lynch syndrome, MEN1, and Carney complex.
Therapeutic Approach
Radical adrenalectomy with en bloc resection. Adjuvant mitotane for high-risk resected ACC. EDP-M (etoposide, doxorubicin, cisplatin + mitotane) for advanced disease. Mitotane blood levels must be maintained in therapeutic range (14-20 mg/L).
Medical Breakthroughs & Hope
Complete surgical removal of localized ACC can be curative. Mitotane provides a unique targeted therapy specific to adrenal tissue. International collaborative efforts (ENSAT network) continue to advance ACC research.
Prognosis & Efficacy70%
Localized ACC: 5-year survival approximately 60-80%. Advanced/metastatic: approximately 10-25%. Complete surgical resection is the strongest predictor of cure.
Myth vs. Clinical Reality
Myth / Fiction
Small adrenal masses are always benign.
Fact / Reality
While most small adrenal incidentalomas are benign, size >4cm, irregular features, and hormonal activity raise suspicion for ACC requiring evaluation.
Myth / Fiction
Adrenal cancer has no treatment.
Fact / Reality
Complete surgical resection can cure localized ACC, and mitotane provides targeted systemic therapy specific to adrenal tissue.
Frequently Asked Questions (FAQ)
What is mitotane?
Mitotane is a drug that selectively destroys adrenal cortical cells. It is unique to ACC treatment and requires careful blood level monitoring.
Why can't the mass be biopsied?
Biopsy of a primary adrenal mass risks tumor seeding along the needle tract. Surgical resection is both diagnostic and therapeutic for suspected ACC.
Is excess cortisol from the tumor dangerous?
Yes. Cortisol excess (Cushing syndrome) causes diabetes, hypertension, osteoporosis, and immunosuppression. Controlling cortisol production is important for patient welfare.
How does this differ from pheochromocytoma?
ACC arises from the adrenal cortex (outer layer) and produces cortisol/androgens/aldosterone. Pheochromocytoma arises from the medulla (inner core) and produces catecholamines. They have different symptoms and treatment.
Is it hereditary?
About 3-10% of ACC is hereditary (Li-Fraumeni, Beckwith-Wiedemann). Genetic testing is recommended, especially for ACC diagnosed in children.